Anti-infection therapy combined with immunotherapy is one of the important research approaches for treating sepsis. However, the combination of anti-infection and immunotherapy therapeutic agents may have an adverse effect on intestinal barrier function. In the present study, it was hypothesized that imipenem combined with low-dose cyclophosphamide (CTX) could improve the sepsis survival rate compared with imipenem treatment alone. In addition, the alterations in the intestinal barrier were investigated and the possible mechanisms of altering intestinal barrier function in septic rats treated with imipenem combined with low-dose CTX or imipenem alone were explored. To investigate the effect of imipenem combined with low-dose CTX on the intestinal barrier, the markers of histopathology, intestinal permeability, intestinal epithelial apoptosis, cytokines interleukin (IL)-6, IL-10 and tumor necrosis factor (TNF)-α, and tight junction proteins zonula occludens (ZO)-1, occludin and claudin-2, were quantitatively and qualitatively evaluated. The results indicated that imipenem combined with low-dose CTX significantly improved the survival rate of rats compared with imipenem alone (P<0.05). However, no significantly difference between the treatment with imipenem combined with low-dose CTX and imipenem treatment alone was indicated with regard to histopathology, intestinal permeability, intestinal epithelial apoptosis and the expression of claudin-2, ZO-1 and TNF-α. However, imipenem combined with low-dose CTX significantly reduced IL-6 and IL-10 expression and significantly increased occludin expression compared with imipenem alone (P<0.05). It was concluded that imipenem combined with low-dose CTX could improve the survival rate of rats with sepsis compared with rats treated with imipenem alone. The present findings suggest that imipenem combined with low-dose CTX may cause damage to the intestinal barrier function and the mechanism may be associated with a reduction in IL-10 expression.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122399 | PMC |
http://dx.doi.org/10.3892/etm.2018.6373 | DOI Listing |
Antibiotics (Basel)
January 2025
Institute of Medical Microbiology, Semmelweis University, 1089 Budapest, Hungary.
In this study, the mechanisms implicated in delafloxacin resistance in strains were investigated. Delafloxacin is a novel, broad-spectrum fluoroquinolone that has been approved for clinical application. In our study, 43 strains were assessed, antimicrobial susceptibility testing was performed via the broth microdilution method, and the minimum inhibitory concentration (MIC) values for ciprofloxacin, delafloxacin, levofloxacin, moxifloxacin, ceftazidime, cefotaxime, and imipenem were determined.
View Article and Find Full Text PDFBMC Pulm Med
January 2025
Element Iowa City (JMI Laboratories), 345 Beaver Kreek Centre, Suite A North Liberty, Iowa, IA, 52317, USA.
Background: Initial antimicrobial therapy for pneumonia is frequently empirical and resistance to antimicrobial agents represents a great challenge to the treatment of patients hospitalized with pneumonia. We evaluated the frequency and antimicrobial susceptibility of Gram-negative bacteria causing pneumonia in US hospitals.
Methods: Bacterial isolates were consecutively collected (1/patient) from patients hospitalized with pneumonia and the susceptibility of Gram-negative bacilli (3,911 Enterobacterales and 2,753 non-fermenters) was evaluated by broth microdilution in a monitoring laboratory.
Microb Pathog
January 2025
Department of Veterinary Public Health and Epidemiology, Lala Lajpat Rai University of Veterinary and Animal Sciences, Hisar, 125004, India. Electronic address:
Bacterial diseases alone or in combination with other pathogens lead to significant economic losses in poultry globally including India. One of these diseases is avian colibacillosis which is caused by avian pathogenic Escherichia coli (APEC). The present study sought to isolate and characterize using in vivo and in vitro assays E.
View Article and Find Full Text PDFJ Infect Dev Ctries
December 2024
Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Introduction: Multidrug-resistant (MDR) bacteria like Proteus species have led to more prolonged hospitalizations, fewer care choices, higher treatment costs, and even death. The present study aims to evaluate the prevalence of MDR Proteus species in clinical samples and to suggest the best therapeutic options for the MDR Proteus species.
Methodology: Clinical samples were collected randomly from five hospitals in Golestan Province, Iran, from February 2017 to July 2019.
BMC Complement Med Ther
January 2025
Department of Faculty of Health Sciences, American University of Madaba, Madaba, Jordan.
Pseudomonas aeruginosa is an opportunistic pathogen belonging to the γ-proteobacteria family, known to cause pneumonia linked with ventilator use and nosocomial infections. With the increasing prevalence of antibiotic-resistant bacteria, there is a pressing need to identify alternatives to conventional antibiotics. Plant-derived substances (PDSs) offer potential not only as antibacterial agents but also as modulators of antibiotic resistance.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!